Trial to Evaluate the Efficacy of a Zinc, Selenium, and L-Tyrosine Supplement in the Prevention of Thyrotoxicosis in Subjects With r25191G/A SEPP1 Polymorphism
NCT ID: NCT06264544
Last Updated: 2025-06-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
150 participants
INTERVENTIONAL
2025-07-30
2025-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Selenium Supplementation in Youths With Autoimmune Thyroiditis
NCT02644707
Selenium Supplementation in Autoimmune Thyroiditis
NCT02013479
Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism
NCT01611896
Selenium in Mild Thyroid Eye Disease in North America
NCT02112643
Selenium Treatment in Autoimmune Thyroiditis (AIT)
NCT00271427
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
zinc, selenium, and L-tyrosine supplementation
zinc, selenium, and L-tyrosine in SEPP1
zinc, selenium, and L-tyrosine in SEPP1 polymorphism
placebo group
Placebo
placebo comparator in SEPP1 polymorphism group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
zinc, selenium, and L-tyrosine in SEPP1
zinc, selenium, and L-tyrosine in SEPP1 polymorphism
Placebo
placebo comparator in SEPP1 polymorphism group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* TPOAb levels \> 300 IU/mL
Exclusion Criteria
* Pregnant or breastfeeding woman
* Subjects with allergy to any of the supplementation component patients with any established diagnosis of thyroid disease
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Center of New Medical Technologies
OTHER
S.LAB (SOLOWAYS)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center of New Medical Technologies
Novosibirsk, Novosibisk Region, Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SW006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.